Confidential Investor Access
Enter the access password from your invitation.
Access limited to invited persons with a pre-existing relationship with the principals. Materials are confidential and not an offer to sell securities.
Enter the access password from your invitation.
Access limited to invited persons with a pre-existing relationship with the principals. Materials are confidential and not an offer to sell securities.
Access limited to invited persons with a pre-existing relationship with the principals — accredited investors and a limited number of sophisticated investors. Entry requires acknowledgment of the confidentiality terms below.
Aethera Medical Group is raising $5,500,000 to open ten integrated clinics across ten cities — each running four clinical engines, CLIA-backed diagnostics, and an IRB-governed research program under USMLE100-governed protocols. Built by the operators behind RegenHealth Physicians of NY.
Regenerative medicine is projected to reach roughly $90B by 2030 (Grand View Research), and more than 50 million U.S. adults live with chronic pain (CDC) — yet protocol-driven regenerative care remains fragmented single-doctor practices. No multi-city brand combines physician-led regenerative procedures, CLIA diagnostics and IRB-governed research under one roof. That is the gap Aethera is engineered to fill.
Our team helped develop RegenHealth Physicians of NY — live, operating clinics — and still supports them. This raise scales our own combined model, with our own leadership and protocols.
rhpny.comMemberships, regenerative procedures, neuropathy programs, diagnostics and IV therapy are predominantly cash-pay — ~60% gross margins, no reimbursement risk, recurring plans.
Ten IRB-governed sites with CLIA diagnostics and USMLE100-governed protocols generate trial data, publications and IP that single clinics can never produce — a compounding moat.
| Category | Who | What they are |
| IV & wellness franchises | Restore Hyper Wellness, Prime IV, The DRIPBaR | Retail hydration & recovery; no physician-led regenerative medicine, diagnostics-light, no research. |
| Ultra-premium longevity | Fountain Life, Human Longevity, Next Health | $20K–$85K/yr, imaging-heavy, concentrated in one or a few cities; not built to scale a standardized clinical format. |
| Regenerative point solutions | Regenexx, QC Kinetix | Single-modality orthobiologics networks; no membership, diagnostics backbone or IRB research layer. |
| Aethera | This platform | Physician-led regenerative + CLIA diagnostics + IRB-governed research, membership-anchored, multi-city — one operating system. |
Competitor set is illustrative of adjacent categories; positioning reflects publicly available descriptions. No competitor is affiliated with or endorses Aethera.
Every clinic runs the same stack in 1,500–3,000 sq ft: shared consultation rooms (100–200 sq ft each), shared front desk, shared compliance. Dr. Morris and Dr. Miller's equipment is compact; Aethera and JIV treatments are injectable and IV-based — so all four engines operate in the same space at maximum utilization. Every room is universal — injections, IV infusions and diagnostic draws all happen in any treatment room, so no single room or lab station bottlenecks throughput and utilization stays high across the schedule.
Physician-led regenerative and cellular therapies — joint, orthopedic and longevity protocols under IRB governance, with biologics sourcing via Auvum Bio.
Dr. Richard Miller's peripheral neuropathy program — laser and light therapies and functional neurology, delivered within each provider's licensed scope under network medical oversight. Compact equipment, high demand, underserved specialty.
Physician-supervised IV therapy lounge — hydration, NAD+ and recovery infusions, administered after a brief medical evaluation under physician standing orders. The retail front door — every JIV patient is a warm referral into the clinical platform.
Athletic performance programs on patented NovaKey™ + SSBreath™ monitoring IP — protocols proven with elite and professional athletes.
Physician-directed regenerative and performance medicine — the modalities our clinics deliver and our IRB-governed research network studies.
Scientific illustrations for orientation. All therapies are physician-directed; certain regenerative modalities are investigational and provided only following individual clinical evaluation.
On-site specialized panels at every clinic — including the proprietary StemAge™ biological-age test — co-designed with USMLE100 and our medical team, with zero additional buildout. Aethera earns a disclosed ~40% revenue share on in-clinic test sales (modeled at ~50% patient test-attach; full sensitivity in the proforma) — a transparent revenue-share, not a markup. Patients are monitored at the clinic level with panels tailored to their protocol.
| Memberships & wellness plans | $45,000 |
| Regenerative procedures + NeuroRenew | $40,000 |
| Clinical diagnostics (SelfHealth) | $20,000 |
| JIV cross-referrals | $15,000 |
| Telehealth consults | $10,000 |
| Online / retail products | $10,000 |
| Fulcrum performance programs | $10,000 |
| Total | $150,000 |
Memberships line = ≈90 members per clinic at a ~$500/mo blended rate. Premium tiers above $1,000/mo are excluded from the base case.
The locked $45K/month membership line is built entirely from the two entry tiers. Everything above them is capacity-capped, application-only upside — deliberately excluded from the financial model, like the R&D credits.
| Signature — the anchor Monthly IV-drip credit · annual StemAge™ + semiannual SelfHealth panel · quarterly clinician wellness review · member pricing on a defined services menu · priority booking | $500/mo in the model |
| Performance Signature + weekly drip credits · monthly Fulcrum coaching on NovaKey™/SSBreath™ protocols · semiannual advanced panel with physician consult · annual NeuroRenew assessment · same-week scheduling | $1,000/mo in the model |
| Summit — by application Performance + physician-directed longevity plan with quarterly reviews · $1,000/month treatment credit toward in-clinic Aethera Cellular Medicine care · dedicated member coordinator · spouse membership included | $4,000/mo capped · upside |
| Aethera Private — household, by invitation Up to four named family members · named lead physician with dedicated access line · RN-administered IV therapy and diagnostic draws at home where state licensure permits · travel desk arranges transportation and accommodation to your nearest clinic, billed at cost · $3,000/month household treatment credit · all regenerative and cellular procedures performed in clinic · five households per metro, published waitlist | $15,000/mo 5 per metro · upside |
Planned architecture with illustrative pricing, subject to regulatory review and market testing in each state. Membership is not insurance, is not a health plan, and does not provide coverage for medical services. All clinical services are rendered by licensed physician-led professional entities; amenity, access and coordination fees are paid to Aethera Medical Group. At-home services will be offered only in markets where required home-care licensure has been obtained; travel and accommodation, where offered, are arranged as a concierge service at member expense. Defined monthly service credits — nothing is unlimited, and no clinical outcome is guaranteed.
Our MDs are employed and work together across the network wherever possible: shared protocols, cross-metro coverage, and IRB governance under one clinical standard rather than isolated solo practitioners.
RNs and physician assistants are engaged through established medical staffing agencies, scaled to each clinic's ramp. Clinical labor flexes with volume — no fixed payroll drag ahead of revenue, and no scramble to hire 60–80 W-2 roles across five states in thirteen months.
Credentialing, compliance, billing and back-office run centrally at the $90K/month corporate line; paired openings share regional management, so each new metro adds clinics without duplicating overhead.
A dedicated per-clinic coordinator owns the patient journey across all four engines — turning a single-service visit into the right next step (an IV patient into a regenerative consult, a diagnostics panel into a longevity protocol), booking cross-engine care and driving the referrals that make the platform compound. This is the role that turns four co-located services into one flywheel.
Staffing-agency rates and physician compensation are inside the $48K/month clinic-opex and $90K/month corporate assumptions in the live model. Final staffing plans are set per state alongside credentialing and CPOM structuring.
This raise funds Vertical 2 — ten full-stack clinics. The other three verticals extend the same protocols, brand and diagnostics with progressively lighter (or heavier) capital, funded by cash flow and future rounds.
← swipe to explore →Licensed corners in existing facilities that join our program — IV, diagnostics and referral intake with minimal buildout. Ideal for upscale hotels: customized treatment menus tailored to travelers and guests.
The full stack: all four engines + SelfHealth diagnostics in one efficient clinical suite. Compact equipment, injectable/IV treatments — maximum revenue per square foot.
The Aethera Wellness Institute concept — every clinic fully built out plus hydrotherapy, spa and recovery. De-risked: Fulcrum already operates flagship locations in NY, NJ and the Dominican Republic.
Telehealth consults, protocol management, product sales and remote monitoring for the patient base — revenue with zero incremental real estate.
Ten clinics across ten cities. Our five launch markets — Boston, Miami, Nashville, Austin and Philadelphia — already have Class-A sites scoped: second-generation, purpose-built medical suites with pre-plumbed exam rooms, compliance-ready layouts and hospital-adjacent corridors — no retail conversion cost, clinical from day one. Five expansion markets — the country's top regenerative-medicine cities — are in active site selection. Scoped suites run compact (~1,100–1,500 sq ft) at the efficient end of our 1,500–3,000 sq ft clinic format; larger footprints follow as each market matures. Average rent across the scoped launch sites: ~$4,500/month — comfortably inside our $48K/month clinic opex assumption.
Every figure computes in real time from the assumptions at left — the same engine as the deck and the proforma. Base Case and Target, side by side — click a card or move the sliders yourself.
Locked, deliberately conservative. What we underwrite — Month 41, 3.83× MOIC.
+39% vs. Base Case. FDA-compliant autologous-only regen + real SelfHealth revenue-share terms (a new revenue line most clinics don't have) — no added capex.
Full stream-by-stream build, an upside/goal case and a fenced founder-vision case are in the editable proforma (Scenario Stack + Regulatory Notes tabs).
| Consolidated | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|
A hybrid Profit Participation structure under Reg D 506(b) — capital returns before the company takes its share, then converts to a permanent stake with research and tax-credit participation.
Funds all ten clinic openings: buildout, Fulcrum deployment, NeuroRenew program, SelfHealth labs, technology, licensing, credentialing, insurance, marketing and working capital. Executed Mutual NDA and definitive offering documents govern.
Investors collectively receive 50% of distributable net profit each month until the full $5.5M is returned. Conservative Base Case completes by month 41; the Target case (~$209K/mo/clinic, Section 05) completes materially faster. Monthly distributions with clinic-level reporting. ("Distributable net profit" will be defined in the operating agreement to match the live model on this page: consolidated clinic-level earnings less corporate overhead.)
After repayment, the investor group retains a permanent 20% stake in Aethera Medical Group LLC — the parent management company; clinical services are delivered through affiliated physician-owned professional entities where state law requires — plus a first right of refusal on all future developments (satellites, flagships, new metros and future rounds) and participation in tax credits and IP generated across the network.
Investors own equity in Aethera Medical Group LLC, the parent management company that holds the cap table, brands, technology and IP. Clinical care is delivered by physician-owned professional entities in each corporate-practice-of-medicine state, under fair-value management agreements — so the structure is compliant by design and investor distributions never touch clinical fees.
Full detail in the structure diagram (PDF) — ownership, milestone tranches, the MSO entity map and returns.
Draft structure; final entity formation, each PC's physician owner and all intercompany agreements are reviewed and finalized with legal counsel (RDK Law & Associates). Not legal advice.
Minimum investment $50,000. The raise is released in tranches tied to clinic openings, so capital is matched to execution and each stage is de-risked by the one before it — the staged go/no-go that protects the downside.
Tranche thresholds govern deployment pacing, not investor economics — every investor receives the same 50%-to-1.0×-then-20% terms regardless of when they commit. Amounts committed to date are subject to closing of definitive documents.
Base case: ~38% gross IRR · 3.83× MOIC at a 10× Year-5 exit.
Illustration derived directly from the base case on this page and scales proportionally from the $50,000 minimum. Returns are pre-tax and not guaranteed; the 20%-stake value is unrealized until a liquidity event, which is not assured. See Key Risks below.
To express our gratitude, every investor in this round may purchase the Founders' Package — a $45,000 allowance for physician-directed regenerative treatment, for $15,000.
Please inquire before selecting: the allowance can be applied across different treatment types, and once you choose an area of focus the treating physician will provide individualized guidance on candidacy, protocol and scheduling. Book a call or write to office@aetheramedical.com.
Optional and entirely separate from the investment itself. Offered at closing and available immediately — investors are introduced to an already-operating clinic in our supported network (matched to the treatment type selected), with no need to wait for an Aethera clinic to open. Usable over 24 months from closing and may be applied to immediate family, with each patient individually evaluated.
The Founders' Package is an optional purchase of clinical services offered in gratitude to participating investors. It is not a security, is not part of the securities offering, and is not a return on investment; it should not form the basis of any investment decision. All care is physician-directed; candidacy and protocol are determined by clinical evaluation, and no treatment outcome is guaranteed. Terms are governed by a separate Founders' Package purchase agreement — not by the securities offering documents.
Profit share sits ahead of company distributions; capital deploys in stages tied to openings, with a pair-by-pair go/no-go gate before each new market; insurance and credentialing lines carry a researched +20% buffer; 6.4% working-capital reserve.
Management earns meaningfully only after investors are repaid. The 50% retained during payback funds growth and the next verticals, not founder distributions.
20% of a 10-clinic platform with franchise-ready systems, a research pipeline, and three unfunded verticals — before any Round 2.
Regulatory. Under FDA's HCT/P framework, only autologous, same-day, minimally-manipulated products (PRP, BMAC, adipose/SVF) are clear to offer without further approval; culture-expanded stem cells, allogeneic products and exosomes are unapproved biologic drugs under active FDA enforcement. The base-case model counts only the compliant category; any culture-expanded/exosome revenue is modeled separately as regulatorily-contingent upside, not underwritten. Corporate-practice-of-medicine rules vary by state and dictate our entity structure.
Execution & ramp. Ten openings in 13 months across five states requires hiring, credentialing and buildout at pace; slower ramps push payback beyond Month 41. The $400K working-capital reserve is sized to the portfolio's modeled cash trough plus a healthcare-specific buffer, not a single-clinic worst case — staged openings with a pair-by-pair go/no-go gate are the mitigation, not a guarantee.
Key people & partners. The model depends on a small leadership team and licensed partner brands and IP; loss of either would hurt.
Competition & demand. Cash-pay wellness is competitive (national IV and longevity chains operate in our metros); membership and procedure demand may underperform the model.
Liquidity & downside. There is no public market for these interests; in the printed downside case, less than half of capital returns in cash within five years. You can lose your entire investment. The definitive offering documents will contain the full risk factors.
Every line ties to the ten-clinic plan. Working capital, credentialing, technology and SelfHealth setup are rebuilt bottom-up from researched 2025/2026 cost benchmarks with an independent verification pass; insurance carries a separate 20% contingency buffer versus market benchmarks — so the plan survives contact with reality.
Ten IRB-governed sites with CLIA diagnostics and USMLE100-governed protocols form a clinical research network — generating publications, protocols, datasets and tax assets on top of clinic cash flow. This value is not included in the base-case MOIC.
Dr. Ali Khan's USMLE100 provides IRB oversight and protocol governance across all sites — 600+ physicians trained (as of July 2026), with published research. Dr. Khan is a medical professor at a Miami medical university. Specialized SelfHealth panels are designed to USMLE100 and medical-team recommendations.
Multi-site outcome datasets, StemAge™ validation studies, NovaKey™/SSBreath™ integrations and treatment protocols — assets that raise exit multiples and license into every future vertical and franchise unit.
IRB-governed clinical research conducted across the network is designed to generate qualified research expenditures. The federal credit (IRC §41) typically yields 6–10% of qualified spend; several launch states add state-level credits. At $1–2M of qualified annual research activity, that is an estimated $60K–$200K per year in credits — participation shared with investors per the offering documents. Sized with tax counsel; treated as upside, not base case.
Healthcare platforms with proprietary protocols, diagnostics and published evidence command premium exit multiples versus service-only comparables. Every point of multiple expansion on Year-5 EBITDA of ~$6.8M is ~$6.8M of enterprise value — of which 20% accrues to the investor group. The research program is how we earn that expansion.
Every format of the platform, organized by vertical — verified floor plans (A-101 through A-106), video walkthroughs and concept interiors. One operating system from 400 to 15,000 square feet. Concept imagery represents intended design direction; actual buildout may vary.
Operators who have opened clinics, trained physicians, built hospital systems and scaled healthcare networks — not advisors, operators.
IRB oversight, CLIA lab infrastructure, USMLE100-governed biologics supply, performance technology and patient-trust systems — in place before Clinic 1 opens.
Dedicated IV therapy brand under the Aethera umbrella. JIV attracts the fast-growing IV wellness market and cross-refers into the full platform — a self-reinforcing loop.
justivclinics.comCLIA-certified, licensed in all 50 states, already operating. On-site specialized panels including StemAge™; Aethera earns a disclosed ~40% revenue share on in-clinic sales — the diagnostics backbone for the entire network and its research programs.
selfhealth.healthIRB oversight, clinical protocol governance and custom panel design. 600+ physicians trained (as of July 2026); published researcher and medical professor at a Miami medical university.
Patented NovaKey™ + SSBreath™ performance intelligence embedded at every location. Operating flagship locations today in New York, New Jersey and the Dominican Republic; protocols developed and proven with elite and professional athletes.
midtownbiohack.comGlobal regenerative platform: stem-cell, MSC-derived exosome and peptide science plus photobiomodulation — several of these therapies are investigational in the U.S. and are offered only where physician-directed and permitted by law. U.S. clinics use only U.S.-compliant products; international research pathways inform protocols, not U.S. treatment.
auvum.bio
Regenerative biologics supplier to the network — advancing a partnership with the ACC bioaccelerator. Their products are deployed in Aethera clinics under USMLE100-governed protocols and processes.
redicell.com
Cybersecurity-first EHR, telehealth and data architecture powering the online clinic (Vertical 4) and clinic-level patient monitoring.
vaultcyberlab.comNo commitment — this simply helps us prioritize conversations and reserve allocation as the round fills. It goes straight to office@aetheramedical.com, confidentially.
Select a day and time that works for you — your request goes straight to office@aetheramedical.com and we confirm by email.
Opportunity, platform, verticals, sites, model, research & IP, deal structure — read it right here.
The full model — assumptions, 5-year summary, investor returns and use of funds — plus the live simulator above.
The whole offering on one page — for quick sharing with your advisors.
The countersignable confidentiality agreement covering these materials.